Each 5 mL contains: 40 mg of Indigotindisulfonate Sodium, in Water for Injection, q.s. pH adjusted, when necessary, with Citric Acid and/or Sodium Citrate.Sterile, nonpyrogenic.
Sufficient Indigo Carmine (indigotindisulfonate) is contained in each 5 mL ampule to permit accurate withdrawal and administration of the full dose.It gives a deep blue solution when dissolved in water.
The structural formula is:
C16H8N2Na2O8S2............................Molecular Weight 466.35
Originally employed as a kidney function test, the chief application of Indigo Carmine (indigotindisulfonate) at present is localizing ureteral orifices during cystoscopy and ureteral catheterization.
DOSAGE AND ADMINISTRATION
Indigo Carmine (indigotindisulfonate) solution is injected either by the intravenous or intramuscular route, and its appearance at the ureteral orifices is watched with the cystoscope in place. The intravenous method is preferred because a 5 mL injection is sufficient.A lesser dosage in infants, children and underweight patients will prevent skin coloration.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
PROTECT FROM LIGHT
Store at controlled room temperature 15°-30°C (59° -86°F).
Indigo Carmine (indigotindisulfonate) Injection
NDC 0517-0375-10...............5 mL ampules..............packaged in boxes of 10
AMERICAN REGENT LABORATORIES, INC. Shirley, NY 11967. Rev.7/98. FDA Rev date: n/a
See "WARNINGS" section.
Drug Abuse And Dependence
Indigo Carmine (indigotindisulfonate) is not a controlled substance listed in any of the Drug Enforcement Administration Schedules.Its use is not known to lead to dependence or abuse.
No information provided.
An occasional idiosyncratic drug reaction may occur. A mild pressor effect may be encountered in some patients. Since precipitation of indigotindisulfonate sodium may occur, Indigo Carmine (indigotindisulfonate) Solution must not be diluted prior to injection or injected with infusion assemblies which were used with other solutions.
Indigo Carmine (indigotindisulfonate) should be stored in the dark, away from direct light, preferably in the original package.
Pregnancy Category C
Animal Reproduction studies have not been conducted with indigotindisulfonate sodium injection.It is also not known whether indigotindisulfonate sodium injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Indigotindisulfonate sodium injection should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Indigo Carmine (indigotindisulfonate) is administered to a nursing woman.
There are no data available describing the signs, symptoms or laboratory findings accompanying overdosage.
No discernible symptoms of toxicity have been observed in mice with an intravenous dose of 200 mg/kg. After intravenous administration the LD80 was established at 300 mg/kg in mice.
Indigo Carmine (indigotindisulfonate) is contraindicated in patients who have previously experienced an adverse reaction following its use.
Indigo Carmine (indigotindisulfonate) is excreted largely by the kidneys, retaining its blue color during passage through the body.
Elimination of the dye begins soon after injection, appearing in the urine within 10 minutes in average cases.The biological half-life is 4 to 5 minutes following intravenous injection. Larger quantities are necessary when intramuscular injection is employed. Appearance time and elimination are delayed following intramuscular injection.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.